Veracyte Names Sangeeta Bhorade, M.D., Medical Director of Pulmonology

 

Photograph of Sangeeta Bhorade, M.D.
Sangeeta Bhorade, M.D.

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has named Sangeeta Bhorade, M.D., medical director of pulmonology. In this role, Dr. Bhorade will lead medical affairs for Veracyte’s pulmonology products, including the Percepta® Bronchial Classifier and Envisia™ Genomic Classifier. Dr. Bhorade will report to Giulia Kennedy, Ph.D., Veracyte’s chief scientific and medical officer.

Prior to joining Veracyte, Dr. Bhorade was professor of medicine and the medical director of the Lung Transplant Program in the Pulmonary and Critical Care Division at Northwestern University Feinberg School of Medicine. During her tenure at Northwestern University, Dr. Bhorade launched its Lung Transplant Program and provided research and clinical expertise as a principal faculty member of the Interstitial Lung Disease Program. She also initiated the Lung Transplant Program at the University of Chicago and served as its medical director.

“We are thrilled to welcome Sangeeta to the Veracyte team,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “As a leader in the field of pulmonology, she brings a wealth of expertise and experience to our pulmonary program and will be instrumental in helping us advance early detection, improve diagnosis and inform treatment decisions for patients.”

“I am excited to join Veracyte and provide clinical and research expertise to help shape the company’s portfolio of pulmonary diagnostics,” said Dr. Bhorade. “I look forward to helping patients get access to these scientifically advanced tests that may help improve their health outcomes and cost of care.”

Dr. Bhorade is board certified in pulmonary and critical care medicine. She received her B.A. from the University of Chicago and her medical degree from the University of Chicago Pritzker School of Medicine. Dr. Bhorade has been voted a “Top Doctor” in pulmonology by U.S. News and World Report for the past seven years.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc.

Santa Casa Hospital System Chooses Carestream for a Unified Diagnostic Workflow

Santa Casa de Misericordia has selected Carestream to replace its legacy diagnostic workflow technology across all seven of its hospitals in Porto Alegre, the capital and largest city of the Brazilian state of Rio Grande do Sul.

American College of Cardiology Thanks Senators McConnell, Kaine for Efforts to Reduce Youth Tobacco...

On behalf of our patients, ACC members thank the Senators for their efforts to reduce youth tobacco use and stand ready to partner with them—and other members of Congress—to enact strong legislation establishing a federal age of 21 for the sale of all tobacco products.”

ResMed Study Finds CPAP Adherence Improved by Remote Monitoring, Self-Monitoring Across 3 Countries

ResMed reports the average adherence to PAP (positive airway pressure), the gold standard for treating sleep apnea, is approximately 50 percent when using legacy technology with no cloud connectivity or remote monitoring capabilities.

Life Image and Bialogics Analytics Partner to Enable Provider Organizations to Optimize Operations, Interoperability

The Life Image and Bialogics partnership will streamline access to analytics of medical imaging in order to help provider organizations enhance operational and financial performance, and improve patient satisfaction.

MediSpin XL™ – Cutting-Edge High-Volume Electrospinning Production Platform for Medical Devices is Launched

The launch of the MediSpin XL™ platform marks a global breakthrough in the controlled large-scale production of well-defined scaffolds for implants and membranes using fibers ranging from nanometer up to micrometer scale.

Hemodialysis Vascular Grafts Market Size Worth $276.5 Million By 2025

Increasing number of patients suffering from chronic kidney diseases (CKD) and growing adoption of biological access products due to technological advancements in the field are some of the factors contributing to revenue growth. Higher number of renal impaired patients and limited availability of suitable kidney donors are promoting hemodialysis procedures in renal impaired patients, which in turn is expected to fuel the demand for vascular grafts over the forecast period.